-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, many pharmaceutical companies have been fined for selling inferior drugs
.
For example, on April 8, the Sichuan Provincial Food and Drug Administration announced an administrative penalty information.
A pharmaceutical company in Sichuan was fined 300,000 yuan for the manufacture and sale of low-quality traditional Chinese medicine decoction pieces and red ginseng tablets
.
The punishment information shows that the production and sale of red ginseng slices of traditional Chinese medicine that do not meet the standards violated Article 98 of the Drug Administration Law, which prohibits the production (including preparation, the same below), the sale, the use of counterfeit medicines, and the The relevant provisions of "medicine" were punished as "the production and sale of traditional Chinese medicine decoction pieces and red ginseng tablets inferior medicine"
.
Sichuan Provincial Food and Drug Administration punished him: 39kg of the illegally produced Chinese herbal decoction pieces and red ginseng slices involved were confiscated, 728 yuan of illegal income was confiscated, and a fine of three times the value of the illegal goods, totaling 300,000 yuan; the above fines and confiscated total 300,728 yuan
.
On April 2, the Guizhou Provincial Food and Drug Administration released information on an administrative penalty case (the 66th issue), involving the case of inferior medicine Shudihuang and other traditional Chinese medicine pieces produced by a pharmaceutical company in Zunyi City
.
According to the second paragraph of Article 117 of the Drug Administration Law, the Guizhou Provincial Food and Drug Administration issued a warning and fine to the pharmaceutical company
.
In March, an administrative penalty information released by Credit Guangzhou showed that a branch of a large pharmaceutical retail enterprise was fined 100,000 yuan for producing and selling inferior drugs
.
The specific unqualified items are: the vitamin D2 content in the multi-dimensional element tablet (21) should be 160-360 units, the actual detection value is 75 units, and the vitamin D2 content in the drug ingredients does not meet the national drug standards
.
Guangzhou Yuexiu District Municipal Bureau of Supervision ordered the branch to correct the behavior of selling inferior medicines whose contents did not meet the national drug standards, and imposed the following administrative penalties: 1.
Confiscation of illegal gains of 224.
12 yuan
.
2.
A fine of 100,000 yuan
.
The total amount of fines and confiscations was 100,224.
12 yuan
.
Behind many pharmaceutical suppliers "eating" fines for producing and selling inferior medicines is the tightening of the supervision of the pharmaceutical industry, which greatly increases the cost of illegality
.
The industry pointed out that, in particular, the implementation of the new version of the "Drug Administration Law" has clear regulations on the scope and fines of counterfeit and inferior drugs
.
According to the new version of the "Drug Administration Law", the scope of counterfeit drugs includes: the ingredients contained in the drugs do not conform to the ingredients specified in the national drug standards; the non-drugs are passed off as drugs or other drugs are passed off as such drugs; spoiled drugs; Indications or functional indications are beyond the specified range
.
The scope of inferior drugs includes: the content of drug ingredients does not meet the national drug standards; contaminated drugs; drugs with no indication or change of expiry date; drugs with no indication or change of product batch number; drugs; other drugs that do not meet the drug standards
.
From the perspective of punishment, according to the new version of the "Drug Administration Law", enterprises that sell fake and inferior drugs will be fined 1.
5 million yuan for selling counterfeit drugs and 100,000 yuan for retailing inferior drugs
.
Judging from some small and medium-sized pharmaceutical companies that have been fined for illegal behavior, the income from the production and sale of counterfeit and inferior drugs is hardly proportional to the fines they eat
.
Drugs are special commodities related to human health.
For pharmaceutical companies, quality is the life of the company.
Only by standardizing production, operation and sales behavior and improving product quality can the development of the company be accelerated.
Otherwise, it is like shooting yourself in the foot.
Go faster
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
For example, on April 8, the Sichuan Provincial Food and Drug Administration announced an administrative penalty information.
A pharmaceutical company in Sichuan was fined 300,000 yuan for the manufacture and sale of low-quality traditional Chinese medicine decoction pieces and red ginseng tablets
.
The punishment information shows that the production and sale of red ginseng slices of traditional Chinese medicine that do not meet the standards violated Article 98 of the Drug Administration Law, which prohibits the production (including preparation, the same below), the sale, the use of counterfeit medicines, and the The relevant provisions of "medicine" were punished as "the production and sale of traditional Chinese medicine decoction pieces and red ginseng tablets inferior medicine"
.
Sichuan Provincial Food and Drug Administration punished him: 39kg of the illegally produced Chinese herbal decoction pieces and red ginseng slices involved were confiscated, 728 yuan of illegal income was confiscated, and a fine of three times the value of the illegal goods, totaling 300,000 yuan; the above fines and confiscated total 300,728 yuan
.
On April 2, the Guizhou Provincial Food and Drug Administration released information on an administrative penalty case (the 66th issue), involving the case of inferior medicine Shudihuang and other traditional Chinese medicine pieces produced by a pharmaceutical company in Zunyi City
.
According to the second paragraph of Article 117 of the Drug Administration Law, the Guizhou Provincial Food and Drug Administration issued a warning and fine to the pharmaceutical company
.
In March, an administrative penalty information released by Credit Guangzhou showed that a branch of a large pharmaceutical retail enterprise was fined 100,000 yuan for producing and selling inferior drugs
.
The specific unqualified items are: the vitamin D2 content in the multi-dimensional element tablet (21) should be 160-360 units, the actual detection value is 75 units, and the vitamin D2 content in the drug ingredients does not meet the national drug standards
.
Guangzhou Yuexiu District Municipal Bureau of Supervision ordered the branch to correct the behavior of selling inferior medicines whose contents did not meet the national drug standards, and imposed the following administrative penalties: 1.
Confiscation of illegal gains of 224.
12 yuan
.
2.
A fine of 100,000 yuan
.
The total amount of fines and confiscations was 100,224.
12 yuan
.
Behind many pharmaceutical suppliers "eating" fines for producing and selling inferior medicines is the tightening of the supervision of the pharmaceutical industry, which greatly increases the cost of illegality
.
The industry pointed out that, in particular, the implementation of the new version of the "Drug Administration Law" has clear regulations on the scope and fines of counterfeit and inferior drugs
.
According to the new version of the "Drug Administration Law", the scope of counterfeit drugs includes: the ingredients contained in the drugs do not conform to the ingredients specified in the national drug standards; the non-drugs are passed off as drugs or other drugs are passed off as such drugs; spoiled drugs; Indications or functional indications are beyond the specified range
.
The scope of inferior drugs includes: the content of drug ingredients does not meet the national drug standards; contaminated drugs; drugs with no indication or change of expiry date; drugs with no indication or change of product batch number; drugs; other drugs that do not meet the drug standards
.
From the perspective of punishment, according to the new version of the "Drug Administration Law", enterprises that sell fake and inferior drugs will be fined 1.
5 million yuan for selling counterfeit drugs and 100,000 yuan for retailing inferior drugs
.
Judging from some small and medium-sized pharmaceutical companies that have been fined for illegal behavior, the income from the production and sale of counterfeit and inferior drugs is hardly proportional to the fines they eat
.
Drugs are special commodities related to human health.
For pharmaceutical companies, quality is the life of the company.
Only by standardizing production, operation and sales behavior and improving product quality can the development of the company be accelerated.
Otherwise, it is like shooting yourself in the foot.
Go faster
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
